课题基金 / 基金详情

Side effect-free cathepsin K targeting drugs for skeletal diseases

Side effect-free cathepsin K targeting drugs for skeletal diseases
用于骨骼疾病的无副作用组织蛋白酶 K 靶向药物
批准号:
523434-2018
负责人:
Bromme, Dieter
金额:
$8.88万
依托单位国家:
加拿大
项目类别:
Collaborative Health Research Projects
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-01-01 至 2019-12-31

项目摘要

项目成果

Bromme, Dieter的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Arthritic diseases affect 15 % of the population and bone cancer is a frequent metastatic side**effect of the most common breast and prostate cancer. Aside from human suffering enormous**financial health care costs are added to the treatment of these diseases. Current treatments**have various shortcomings and side effects, which include increased cancer risks, atypical**fractures, bone necrosis, infections, and vascular problems. There is clearly a need for more**effective and safer treatments. Unfortunately, little progress has been made in recent years.**Most treatments attack rather non-specifically entire cells or block complex pathways, which**is likely causing the side effects. In contrast, the protease, cathepsin K, is solely responsible**for the bone degradation and significantly contributes to joint erosion. Its inhibition has been**shown to effectively reduce fracture rates in post-menopausal women. However, this**treatment also had severe side effects leading to the termination of the further development of**cathepsin K inhibitors. Our research has identified and verified a novel type of cathepsin K**inhibitors without causing any of the side effects seen in clinical trials. Interestingly, a major**source of these compounds are certain Chinese herbs traditionally used in skeletal diseases.**Recently, we have shown the efficacy of one of these compounds in an osteoporosis model**without any observable side effects. This project will expand this approach and will generate**more potent and druggable derivatives from the herbal compounds. Compounds will be**analyzed in arthritis and bone cancer mouse models. We anticipate that these compounds will**have a superior efficacy with no or fewer side effects than current treatment regimes. This**project requires a strong interdisciplinary collaboration between chemists, pharmaceutical**scientists, biochemists, and animal model researchers and will provide an excellent**opportunity for the training of students.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2022
  • 负责人:
    Bromme, Dieter
  • 依托单位:
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2021
  • 负责人:
    Bromme, Dieter
  • 依托单位:
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2020
  • 负责人:
    Bromme, Dieter
  • 依托单位:
Side effect-free cathepsin K targeting drugs for skeletal diseases
  • 批准号:
    523434-2018
  • 项目类别:
    Collaborative Health Research Projects
  • 资助金额:
    $17.34万
  • 财政年份:
    2019
  • 负责人:
    Bromme, Dieter
  • 依托单位:
国内基金
海外基金
Crocin 抑制 Hartley 豚鼠早期骨关节炎发生的 作用机制研究
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
  • 批准号:
    82371103
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    阮静
  • 依托单位:
LINC00673调控HIF-1α促进Warburg effect在子宫内膜蜕膜化中的作用和机制研究
  • 批准号:
    82060281
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    34.0万元
  • 批准年份:
    2020
  • 负责人:
    朱元昌
  • 依托单位:
PKM2调控H2B泛素化修饰的分子机制及其在肿瘤代谢中的作用研究
  • 批准号:
    81773009
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2017
  • 负责人:
    陈苏
  • 依托单位: